Carbometyx

Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says
Fierce Pharma
Thu, 08/24/23 - 08:37 pm
Carbometyx
Exelixis
clinical trials
neuroendocrine tumors
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Mon, 08/21/23 - 10:02 am
Exelixis
Ipsen
Carbometyx
prostate cancer